OKYO - Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study | Benzinga
OKYO Pharma Limited (NASDAQ:OKYO) announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED).
These new findings include:
- A statistically significant and durable reduction in ocular pain
- Statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study – a clinically important endpoint
- Multiple symptomatic improvements as observed by both data obtained from patient clinic visits as well as data from patient daily symptom diaries
These results complement the statistically significant effects reported earlier on ...